Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | SDCBP | O00560 | 3/20 | 0.45 |
| ▸ | SDC2 | P34741 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232334 | 1.00 | NPSR1 (0.53) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2081229 | 1.00 | NPSR1 (0.53) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16027492 | 0.98 | NPSR1 (0.51) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL18766164 | 0.96 | NPSR1 (0.50) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL29380611 | 0.92 | NPSR1 (0.47) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL31064974 | 0.88 | NPSR1 (0.44) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4968369 | 0.87 | NPSR1 (0.43) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL29531660 | 0.87 | NPSR1 (0.43) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15756817 | 0.87 | NPSR1 (0.43) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15756824 | 0.87 | NPSR1 (0.43) | NPSR1SDCBPSDC2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4709912-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BioAtla, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260014264-A1 | SPECIFIC TOPOISOMERASE INHIBITOR, USE AS ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | BIOBRICS LIFE SCIENCE (NANTONG) CO., LTD. (CN) | 2026-01-15 | — | — | US | claimed |
| US-20250051463-A1 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2025-02-13 | — | — | US | claimed |
| WO-2025027472-A2 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2025-02-06 | — | — | WO | claimed |
| CN-119215026-A | Antibacterial drug auxiliary agent and application thereof | 湖北金元惠生物科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-119224161-A | Method for detecting various dipeptides in rumen fluid of ruminant | 中国科学院亚热带农业生态研究所 | 2024-12-31 | — | — | CN | claimed |
| WO-2024255873-A1 | METHOD FOR PREPARING ANTIBODY-DRUG CONJUGATE | 江苏迈威康新药研发有限公司 | 2024-12-19 | — | — | WO | claimed |
| CN-119139490-A | Method for preparing antibody drug conjugate | 江苏迈威康新药研发有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024232976-A1 | PROTEIN THERAPEUTICS FOR TREATMENT OF SENESCENT CELLS | BIOATLA, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2009-04-23 | — | — | US | claimed |
| CN-101316582-A | Method of treating muscle loss | NESTEC SA (CH) | 2008-12-03 | — | — | CN | claimed |
| EP-1957061-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2008-08-20 | — | — | EP | claimed |
| EP-1940252-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007064618-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2007-06-07 | — | — | WO | claimed |
| WO-2007053390-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2007-05-10 | — | — | WO | claimed |
| US-6429220-B1 | COMPRISES AN ISOTHIAZOLONE COMPOUND AND AN AMINOCARBOXYLIC ACID | KURITA WATER INDUSTRIES LTD. (JP) | 2002-08-06 | — | — | US | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014264-A1 | SPECIFIC TOPOISOMERASE INHIBITOR, USE AS ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR | TOP1, TOP2A, TOP2B | NPSR1 4768/4885SDCBP 2856/4885SDC2 3207/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | NPSR1 1831/4885SDCBP 2779/4885SDC2 638/4885 |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | BCAT2, CPT1B, BCAT1 | NPSR1 4161/4885SDCBP 3338/4885SDC2 3900/4885 |
| US-20250051463-A1 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME | IL23R, CD63, CD2 | NPSR1 3213/4885SDCBP 104/4885SDC2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.